Question special
Resident

Drs. Trivedi, and Shoptaw thank you so much for the opportunity of exchanging our ideas in this very interesting and relevant discussion.
Despite stimulants being widely used worldwide, we have yet to see pharmacotherapy with strong results for the treatment of methamphetamine dependence.

Upon reviewing the existing evidence, it seems that these studies face the challenge of treatment non-adherence. An extended-release injectable would in fact improve treatment retention, but at a greater cost when compared to its oral formulation. When discussing cost-effectiveness, how would you suggest we overcome this potential barrier in a primary care setting?